Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1991 Dec;59(12):4576–4582. doi: 10.1128/iai.59.12.4576-4582.1991

Antibody to a 145-kilodalton outer membrane protein has bactericidal activity and protective activity against experimental bacteremia caused by a Brazilian purpuric fever isolate of Haemophilus influenzae biogroup aegyptius. The Brazilian Purpuric Fever Study Group.

L G Rubin 1, A Rizvi 1
PMCID: PMC259080  PMID: 1937817

Abstract

The immunologic basis for protection against Brazilian purpuric fever, a septicemic infection associated with Haemophilus influenzae biogroup aegyptius bacteremia, is unknown. Passive immunization of infant rats with antiserum to whole bacterial cells of the homologous strain protects them from experimental bacteremia following bacterial challenge. In immunoblotting, antibody to a 145-kDa protein (P145) was present in protective antisera but not in nonprotective antisera. As judged by analysis of the antibodies eluted from whole bacterial cells and the agglutination of bacteria by antisera to P145, this protein is surface exposed. We prepared monospecific rat antisera to this protein by three methods: (i) immunization with whole bacterial cells and absorption with a Brazilian purpuric fever strain not expressing P145, (ii) immunization with gel-purified P145, and (iii) immunization with a P145-expressing transformant of a laboratory H. influenzae strain expressing this protein and absorption of the antiserum with the laboratory H. influenzae strain. These antisera had low antilipooligosaccharide antibody titers, were reactive only with P145, and had bactericidal activity in vitro. Following passive immunization, these antisera partially protected infant rats from bacteremia resulting from intraperitoneal challenge with bacteria. As assessed by immunoblotting, pooled adult human sera contained antibodies reactive with P145. Antibody to P145 may contribute to protection against Brazilian purpuric fever.

Full text

PDF
4578

Images in this article

4579Image
on p.4579
4579Image
on p.4579
4579Image
on p.4579
4580Image
on p.4580
4580Image
on p.4580
4581Image
on p.4581

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson P., Johnston R. B., Jr, Smith D. H. Human serum activities against Hemophilus influenzae, type b. J Clin Invest. 1972 Jan;51(1):31–38. doi: 10.1172/JCI106793. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Carlone G. M., Gorelkin L., Gheesling L. L., Erwin A. L., Hoiseth S. K., Mulks M. H., O'Connor S. P., Weyant R. S., Myrick J., Rubin L. Potential virulence-associated factors in Brazilian purpuric fever. Brazilian Purpuric Fever Study Group. J Clin Microbiol. 1989 Apr;27(4):609–614. doi: 10.1128/jcm.27.4.609-614.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Carlone G. M., Sottnek F. O., Plikaytis B. D. Comparison of outer membrane protein and biochemical profiles of Haemophilus aegyptius and Haemophilus influenzae biotype III. J Clin Microbiol. 1985 Nov;22(5):708–713. doi: 10.1128/jcm.22.5.708-713.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Engleberg N. C., Pearlman E., Dixon D., Eisenstein B. I. Antibodies isolated by using cloned surface antigens recognize antigenically related components of Legionella pneumophila and other Legionella species. J Immunol. 1986 Feb 15;136(4):1415–1417. [PubMed] [Google Scholar]
  5. Granoff D. M., Munson R. S., Jr Prospects for prevention of Haemophilus influenzae type b disease by immunization. J Infect Dis. 1986 Mar;153(3):448–461. doi: 10.1093/infdis/153.3.448. [DOI] [PubMed] [Google Scholar]
  6. Harrison L. H., da Silva G. A., Pittman M., Fleming D. W., Vranjac A., Broome C. V. Epidemiology and clinical spectrum of Brazilian purpuric fever. Brazilian Purpuric Fever Study Group. J Clin Microbiol. 1989 Apr;27(4):599–604. doi: 10.1128/jcm.27.4.599-604.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kimura A., Hansen E. J. Antigenic and phenotypic variations of Haemophilus influenzae type b lipopolysaccharide and their relationship to virulence. Infect Immun. 1986 Jan;51(1):69–79. doi: 10.1128/iai.51.1.69-79.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Moxon E. R., Deich R. A., Connelly C. Cloning of chromosomal DNA from Haemophilus influenzae. Its use for studying the expression of type b capsule and virulence. J Clin Invest. 1984 Feb;73(2):298–306. doi: 10.1172/JCI111214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Rubin L. G. Anticapsular antibody requirements for protection against experimental Haemophilus influenzae type b bacteremia after splenectomy. Infect Immun. 1988 Apr;56(4):984–986. doi: 10.1128/iai.56.4.984-986.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Rubin L. G., Gloster E. S., Carlone G. M. An infant rat model of bacteremia with Brazilian purpuric fever isolates of Hemophilus influenzae biogroup aegyptius. Brazilian Purpuric Fever Study Group. J Infect Dis. 1989 Sep;160(3):476–482. doi: 10.1093/infdis/160.3.476. [DOI] [PubMed] [Google Scholar]
  11. Shenep J. L., Munson R. S., Jr, Granoff D. M. Human antibody responses to lipopolysaccharide after meningitis due to Haemophilus influenzae type b. J Infect Dis. 1982 Feb;145(2):181–190. doi: 10.1093/infdis/145.2.181. [DOI] [PubMed] [Google Scholar]
  12. Sleytr U. B., Messner P. Crystalline surface layers on bacteria. Annu Rev Microbiol. 1983;37:311–339. doi: 10.1146/annurev.mi.37.100183.001523. [DOI] [PubMed] [Google Scholar]
  13. Swaminathan B., Mayer L. W., Bibb W. F., Ajello G. W., Irino K., Birkness K. A., Garon C. F., Reeves M. W., de Cunto Brandileone M. C., Sottnek F. O. Microbiology of Brazilian purpuric fever and diagnostic tests. Brazilian Purpuric Fever Study Group. J Clin Microbiol. 1989 Apr;27(4):605–608. doi: 10.1128/jcm.27.4.605-608.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350–4354. doi: 10.1073/pnas.76.9.4350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Zwahlen A., Winkelstein J. A., Moxon E. R. Participation of complement in host defense against capsule-deficient Haemophilus influenzae. Infect Immun. 1983 Nov;42(2):708–715. doi: 10.1128/iai.42.2.708-715.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES